Etamsylate

PreclinicalSmall molecule

FFirst Affiliated Hospital of Zhejiang University

Etamsylate is one of 4 small molecule programs targeting Pancreatectomy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PancreatectomyActive, not recruiting

PancreatectomyPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Pancreatectomy

#DrugCompanyPhaseTrials

Indocin

LLife Extension Foundation Inc.

Signifor

1 3

Botox

RRevance Therapeutics, Inc.

Phase 2

1 4

Etamsylate

FFirst Affiliated Hospital of Zhejiang University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Bleeding

NCT07442513

Clinical

Trials by Indication[1]

Pancreatectomy1 trial

Can Administration of Etamsylate Reduce Postpancreatectomy Hemorrhage

Unknown status·UUniversity of Sfax·N/A·NCT06190535·20 enrolled

Bleeding1 trial

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT07442513·404 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Etamsylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Etamsylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Etamsylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFirst Affiliated Hospital of Zhejiang University

Etamsylate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pancreatectomy1 trial

Bleeding1 trial

References

Drug Info

Quick Facts

Related News